Aceto, a US virtual manufacturer of specialty materials for life sciences, nutrition, agricultural and advanced technology end markets, has acquired Syntor Fine Chemicals, an asset-light manufacturer of fine chemicals for pharmaceutical and other life sciences end markets.

Terms of the deal were not disclosed.

Port Washington, New York-based Aceto said the acquisition strengthens its offering of differentiated specialty materials and solutions in life sciences and advanced technology end markets while also increasing the scale of its portfolio.

Going forward, Syntor will operate under the name “Syntor by Aceto,” and the US company said “it is intended that all employees will be retained in their current roles.”

The acquisition of Runcorn, UK-based Syntor is an important step in Aceto’s strategic growth plan, said CEO Gilles Cottier. Adding the British firm’s synthesis and formulation capabilities will enhance the new owner’s existing services and expand its value-added offerings in life sciences materials, providing greater product customization, he commented.

Many of Syntor’s products are developed in-house for well-placed customers in the life sciences, pharmaceutical, agrochemical, aroma and electronics industries.

Simon Knowles, managing partner of Syntor, said the two companies are “well aligned in their culture and drive to maximize value to customers through sourcing and development of complex chemistries.”  The partnership creates significant cross-sell opportunities that benefit customers and supply partners to both businesses, he added.